1982
Histologic Progression in Non-Hodgkin’s Lymphoma
Hubbard S, Chabner B, DeVita V, Simon R, Berard C, Jones R, Garvin A, Canellos G, Osborne C, Young R. Histologic Progression in Non-Hodgkin’s Lymphoma. Blood 1982, 59: 258-264. DOI: 10.1182/blood.v59.2.258.258.Peer-Reviewed Original ResearchNodular lymphomaHistological progressionLymphoma patientsHistiocytic cell typesProlonged disease-free survivalNon-Hodgkin's lymphoma patientsAssociated with prolonged survivalCell typesIntensive combination chemotherapyNon-Hodgkin's lymphomaDisease-free survivalResponse to chemotherapyNon-HodgkinCombination chemotherapyDiffuse histologyIntensive chemotherapyClinical courseBiopsy specimensProlonged survivalWorsened prognosisLymphomaNodular patternBiopsyClinical trialsDrug treatment
1976
Central nervous system complications in patients with diffuse histiocytic and undifferentiated lymphoma: leukemia revisited.
Bunn P, Schein P, Banks P, DeVita V. Central nervous system complications in patients with diffuse histiocytic and undifferentiated lymphoma: leukemia revisited. Blood 1976, 47: 3-10. PMID: 1106798, DOI: 10.1182/blood.v47.1.3.bloodjournal4713.Peer-Reviewed Original ResearchConceptsLeptomeningeal lymphomaCentral nervous systemHistologic types of non-Hodgkin's lymphomasProgression of systemic diseaseCentral nervous system complicationsCentral nervous system therapyProphylactic CNS therapySite of relapseBone marrow involvementNon-Hodgkin's lymphomaIntrathecal drug administrationPatient's clinical courseCerebrospinal fluid cytologyResponse to therapyNervous system complicationsNervous system therapyBone marrow cavityUndifferentiated lymphomaMarrow involvementClinical remissionSystemic therapyCNS therapyClinical courseHistological typeSystemic complicationsCentral Nervous System Complications in Patients With Diffuse Histiocytic and Undifferentiated Lymphoma: Leukemia Revisited
Bunn P, Schein P, Banks P, DeVita V. Central Nervous System Complications in Patients With Diffuse Histiocytic and Undifferentiated Lymphoma: Leukemia Revisited. Blood 1976, 47: 3-10. DOI: 10.1182/blood.v47.1.3.3.Peer-Reviewed Original ResearchLeptomeningeal lymphomaCentral nervous systemHistologic types of non-Hodgkin's lymphomasProgression of systemic diseaseCentral nervous system complicationsCentral nervous system therapyProphylactic CNS therapySite of relapseBone marrow involvementNon-Hodgkin's lymphomaIntrathecal drug administrationPatient's clinical courseCerebrospinal fluid cytologyResponse to therapyNervous system complicationsNervous system therapyBone marrow cavityUndifferentiated lymphomaMarrow involvementClinical remissionSystemic therapyCNS therapyClinical courseHistological typeSystemic complications
1975
Patterns of involvement with malignant lymphoma and implications for treatment decision making.
Johnson R, DeVita V, Kun L, Chabner B, Chretien P, Berard C, Johnson S. Patterns of involvement with malignant lymphoma and implications for treatment decision making. British Journal Of Cancer. Supplement 1975, 2: 237-41. PMID: 1182071, PMCID: PMC2149575.Peer-Reviewed Original ResearchConceptsMalignant lymphomaTreatment decisionsPresentation of lymphomaPrimary extranodal lymphomaMajority of patientsUntreated malignant lymphomaPattern of involvementMajority of casesLymphatic irradiationProspective stagingSurgical stagingExtranodal lymphomaExtranodal sitesHaematogenous spreadSystemic treatmentClinical courseConsecutive patientsLymph nodesDisease extentHodgkin's diseaseDisseminated involvementAppropriate treatmentLymphatic extensionPrimary manifestationHigh dose
1972
Phytohemagglutinin-induced Lymphocyte Transformation: The Relationship to Prognosis of Hodgkin's Disease
Corder M, Young R, Brown R, DeVita V. Phytohemagglutinin-induced Lymphocyte Transformation: The Relationship to Prognosis of Hodgkin's Disease. Blood 1972, 39: 595-601. PMID: 5022714, DOI: 10.1182/blood.v39.5.595.595.Peer-Reviewed Original Research